SrasV1, PascalFrancis, Corpus, bibRecord, 000221

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

Identifieur interne : 000221 ( PascalFrancis/Corpus ); précédent : 000220; suivant : 000222

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

Auteurs : MIN ZHUANG ; HONG JIANG ; Yasuhiro Suzuki ; XIAOGUANG LI ; PENG XIAO ; Takashi Tanaka ; HONG LING ; BAOFENG YANG ; Hiroki Saitoh ; LIANFENG ZHANG ; CHUAN QIN ; Kazuo Sugamura ; Toshio Hattori

Source :

Antiviral research [ 0166-3542 ] ; 2009.

RBID : Pascal:09-0210832

Descripteurs français

Pascal (Inist)
- Extrait, Virus syndrome respiratoire aigu sévère, Infection, Origine végétale, Plante médicinale, Transferrine, Récepteur biologique, Activité biologique, Antiviral, Cinnamomum, Lentivirus, In vitro.

English descriptors

KwdEn :
- Antiviral, Biological activity, Biological receptor, Cinnamomum, Extract, In vitro, Infection, Lentivirus, Medicinal plant, Plant origin, Severe acute respiratory syndrome virus, Transferrin.

Abstract

We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC_50S, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC_50S, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC_50S, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 82`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection`
A11	`01`	`1`		`@1 MIN ZHUANG`
A11	`02`	`1`		`@1 HONG JIANG`
A11	`03`	`1`		`@1 SUZUKI (Yasuhiro)`
A11	`04`	`1`		`@1 XIAOGUANG LI`
A11	`05`	`1`		`@1 PENG XIAO`
A11	`06`	`1`		`@1 TANAKA (Takashi)`
A11	`07`	`1`		`@1 HONG LING`
A11	`08`	`1`		`@1 BAOFENG YANG`
A11	`09`	`1`		`@1 SAITOH (Hiroki)`
A11	`10`	`1`		`@1 LIANFENG ZHANG`
A11	`11`	`1`		`@1 CHUAN QIN`
A11	`12`	`1`		`@1 SUGAMURA (Kazuo)`
A11	`13`	`1`		`@1 HATTORI (Toshio)`
A14	`01`			`@1 Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University @2 980-8574 @3 JPN @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 9 aut. @Z 13 aut.`
A14	`02`			`@1 Department of Medical Microbiology, Harbin Medical University @2 Harbin, 150086 @3 CHN @Z 1 aut. @Z 7 aut.`
A14	`03`			`@1 Institute of Laboratory Animal Science, Chinese Academy of Medical Science @2 Beijing, 100021 @3 CHN @Z 2 aut. @Z 10 aut. @Z 11 aut.`
A14	`04`			`@1 Graduate School of Biomedical Sciences, Nakasaki University @2 Nakasaki, 852-8131 @3 JPN @Z 6 aut.`
A14	`05`			`@1 Department of Pharmacology, Harbin Medical University @2 Harbin, 150086 @3 CHN @Z 8 aut.`
A14	`06`			`@1 Department of Immunology, Tohoku University @2 980-8574 @3 JPN @Z 12 aut.`
A20				`@1 73-81`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000184929350100`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 3/4 p.`
A47	`01`	`1`		`@0 09-0210832`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC_50S, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC_50S, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC_50S, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Extrait @5 01`
C03	`01`	`X`	`ENG`	`@0 Extract @5 01`
C03	`01`	`X`	`SPA`	`@0 Extracto @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Infection @5 03`
C03	`03`	`X`	`ENG`	`@0 Infection @5 03`
C03	`03`	`X`	`SPA`	`@0 Infección @5 03`
C03	`04`	`X`	`FRE`	`@0 Origine végétale @5 04`
C03	`04`	`X`	`ENG`	`@0 Plant origin @5 04`
C03	`04`	`X`	`SPA`	`@0 Origen vegetal @5 04`
C03	`05`	`X`	`FRE`	`@0 Plante médicinale @5 05`
C03	`05`	`X`	`ENG`	`@0 Medicinal plant @5 05`
C03	`05`	`X`	`SPA`	`@0 Planta medicinal @5 05`
C03	`06`	`X`	`FRE`	`@0 Transferrine @5 06`
C03	`06`	`X`	`ENG`	`@0 Transferrin @5 06`
C03	`06`	`X`	`SPA`	`@0 Transferrina @5 06`
C03	`07`	`X`	`FRE`	`@0 Récepteur biologique @5 07`
C03	`07`	`X`	`ENG`	`@0 Biological receptor @5 07`
C03	`07`	`X`	`SPA`	`@0 Receptor biológico @5 07`
C03	`08`	`X`	`FRE`	`@0 Activité biologique @5 09`
C03	`08`	`X`	`ENG`	`@0 Biological activity @5 09`
C03	`08`	`X`	`SPA`	`@0 Actividad biológica @5 09`
C03	`09`	`X`	`FRE`	`@0 Antiviral @5 10`
C03	`09`	`X`	`ENG`	`@0 Antiviral @5 10`
C03	`09`	`X`	`SPA`	`@0 Antiviral @5 10`
C03	`10`	`X`	`FRE`	`@0 Cinnamomum @2 NS @5 11`
C03	`10`	`X`	`ENG`	`@0 Cinnamomum @2 NS @5 11`
C03	`10`	`X`	`SPA`	`@0 Cinnamomum @2 NS @5 11`
C03	`11`	`X`	`FRE`	`@0 Lentivirus @2 NW @5 12`
C03	`11`	`X`	`ENG`	`@0 Lentivirus @2 NW @5 12`
C03	`11`	`X`	`SPA`	`@0 Lentivirus @2 NW @5 12`
C03	`12`	`X`	`FRE`	`@0 In vitro @5 13`
C03	`12`	`X`	`ENG`	`@0 In vitro @5 13`
C03	`12`	`X`	`SPA`	`@0 In vitro @5 13`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Lauraceae @2 NS`
C07	`05`	`X`	`ENG`	`@0 Lauraceae @2 NS`
C07	`05`	`X`	`SPA`	`@0 Lauraceae @2 NS`
C07	`06`	`X`	`FRE`	`@0 Dicotyledones @2 NS`
C07	`06`	`X`	`ENG`	`@0 Dicotyledones @2 NS`
C07	`06`	`X`	`SPA`	`@0 Dicotyledones @2 NS`
C07	`07`	`X`	`FRE`	`@0 Angiospermae @2 NS`
C07	`07`	`X`	`ENG`	`@0 Angiospermae @2 NS`
C07	`07`	`X`	`SPA`	`@0 Angiospermae @2 NS`
C07	`08`	`X`	`FRE`	`@0 Spermatophyta @2 NS`
C07	`08`	`X`	`ENG`	`@0 Spermatophyta @2 NS`
C07	`08`	`X`	`SPA`	`@0 Spermatophyta @2 NS`
C07	`09`	`X`	`FRE`	`@0 Retroviridae @2 NW`
C07	`09`	`X`	`ENG`	`@0 Retroviridae @2 NW`
C07	`09`	`X`	`SPA`	`@0 Retroviridae @2 NW`
C07	`10`	`X`	`FRE`	`@0 Pharmacognosie @5 37`
C07	`10`	`X`	`ENG`	`@0 Pharmacognosy @5 37`
C07	`10`	`X`	`SPA`	`@0 Farmacognosia @5 37`
N21				`@1 152`

Format Inist (serveur)

NO :	PASCAL 09-0210832 INIST
ET :	Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection
AU :	MIN ZHUANG; HONG JIANG; SUZUKI (Yasuhiro); XIAOGUANG LI; PENG XIAO; TANAKA (Takashi); HONG LING; BAOFENG YANG; SAITOH (Hiroki); LIANFENG ZHANG; CHUAN QIN; SUGAMURA (Kazuo); HATTORI (Toshio)
AF :	Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University/980-8574/Japon (1 aut., 3 aut., 4 aut., 5 aut., 9 aut., 13 aut.); Department of Medical Microbiology, Harbin Medical University/Harbin, 150086/Chine (1 aut., 7 aut.); Institute of Laboratory Animal Science, Chinese Academy of Medical Science/Beijing, 100021/Chine (2 aut., 10 aut., 11 aut.); Graduate School of Biomedical Sciences, Nakasaki University/Nakasaki, 852-8131/Japon (6 aut.); Department of Pharmacology, Harbin Medical University/Harbin, 150086/Chine (8 aut.); Department of Immunology, Tohoku University/980-8574/Japon (12 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 2009; Vol. 82; No. 1; Pp. 73-81; Bibl. 3/4 p.
LA :	Anglais
EA :	We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC_50S, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC_50S, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC_50S, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.
CC :	002B02S05
FD :	Extrait; Virus syndrome respiratoire aigu sévère; Infection; Origine végétale; Plante médicinale; Transferrine; Récepteur biologique; Activité biologique; Antiviral; Cinnamomum; Lentivirus; In vitro
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Lauraceae; Dicotyledones; Angiospermae; Spermatophyta; Retroviridae; Pharmacognosie
ED :	Extract; Severe acute respiratory syndrome virus; Infection; Plant origin; Medicinal plant; Transferrin; Biological receptor; Biological activity; Antiviral; Cinnamomum; Lentivirus; In vitro
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Lauraceae; Dicotyledones; Angiospermae; Spermatophyta; Retroviridae; Pharmacognosy
SD :	Extracto; Severe acute respiratory syndrome virus; Infección; Origen vegetal; Planta medicinal; Transferrina; Receptor biológico; Actividad biológica; Antiviral; Cinnamomum; Lentivirus; In vitro
LO :	INIST-18839.354000184929350100
ID :	09-0210832

Links to Exploration step

Pascal:09-0210832

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection</title>
<author><name sortKey="Min Zhuang" sort="Min Zhuang" uniqKey="Min Zhuang" last="Min Zhuang">MIN ZHUANG</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hong Jiang" sort="Hong Jiang" uniqKey="Hong Jiang" last="Hong Jiang">HONG JIANG</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Yasuhiro" sort="Suzuki, Yasuhiro" uniqKey="Suzuki Y" first="Yasuhiro" last="Suzuki">Yasuhiro Suzuki</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiaoguang Li" sort="Xiaoguang Li" uniqKey="Xiaoguang Li" last="Xiaoguang Li">XIAOGUANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng Xiao" sort="Peng Xiao" uniqKey="Peng Xiao" last="Peng Xiao">PENG XIAO</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanaka, Takashi" sort="Tanaka, Takashi" uniqKey="Tanaka T" first="Takashi" last="Tanaka">Takashi Tanaka</name>
<affiliation><inist:fA14 i1="04"><s1>Graduate School of Biomedical Sciences, Nakasaki University</s1>
<s2>Nakasaki, 852-8131</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hong Ling" sort="Hong Ling" uniqKey="Hong Ling" last="Hong Ling">HONG LING</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baofeng Yang" sort="Baofeng Yang" uniqKey="Baofeng Yang" last="Baofeng Yang">BAOFENG YANG</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pharmacology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saitoh, Hiroki" sort="Saitoh, Hiroki" uniqKey="Saitoh H" first="Hiroki" last="Saitoh">Hiroki Saitoh</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lianfeng Zhang" sort="Lianfeng Zhang" uniqKey="Lianfeng Zhang" last="Lianfeng Zhang">LIANFENG ZHANG</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuan Qin" sort="Chuan Qin" uniqKey="Chuan Qin" last="Chuan Qin">CHUAN QIN</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sugamura, Kazuo" sort="Sugamura, Kazuo" uniqKey="Sugamura K" first="Kazuo" last="Sugamura">Kazuo Sugamura</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Immunology, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattori, Toshio" sort="Hattori, Toshio" uniqKey="Hattori T" first="Toshio" last="Hattori">Toshio Hattori</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0210832</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0210832 INIST</idno>
<idno type="RBID">Pascal:09-0210832</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000221</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection</title>
<author><name sortKey="Min Zhuang" sort="Min Zhuang" uniqKey="Min Zhuang" last="Min Zhuang">MIN ZHUANG</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hong Jiang" sort="Hong Jiang" uniqKey="Hong Jiang" last="Hong Jiang">HONG JIANG</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Yasuhiro" sort="Suzuki, Yasuhiro" uniqKey="Suzuki Y" first="Yasuhiro" last="Suzuki">Yasuhiro Suzuki</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiaoguang Li" sort="Xiaoguang Li" uniqKey="Xiaoguang Li" last="Xiaoguang Li">XIAOGUANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng Xiao" sort="Peng Xiao" uniqKey="Peng Xiao" last="Peng Xiao">PENG XIAO</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanaka, Takashi" sort="Tanaka, Takashi" uniqKey="Tanaka T" first="Takashi" last="Tanaka">Takashi Tanaka</name>
<affiliation><inist:fA14 i1="04"><s1>Graduate School of Biomedical Sciences, Nakasaki University</s1>
<s2>Nakasaki, 852-8131</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hong Ling" sort="Hong Ling" uniqKey="Hong Ling" last="Hong Ling">HONG LING</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baofeng Yang" sort="Baofeng Yang" uniqKey="Baofeng Yang" last="Baofeng Yang">BAOFENG YANG</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pharmacology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saitoh, Hiroki" sort="Saitoh, Hiroki" uniqKey="Saitoh H" first="Hiroki" last="Saitoh">Hiroki Saitoh</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lianfeng Zhang" sort="Lianfeng Zhang" uniqKey="Lianfeng Zhang" last="Lianfeng Zhang">LIANFENG ZHANG</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuan Qin" sort="Chuan Qin" uniqKey="Chuan Qin" last="Chuan Qin">CHUAN QIN</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sugamura, Kazuo" sort="Sugamura, Kazuo" uniqKey="Sugamura K" first="Kazuo" last="Sugamura">Kazuo Sugamura</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Immunology, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattori, Toshio" sort="Hattori, Toshio" uniqKey="Hattori T" first="Toshio" last="Hattori">Toshio Hattori</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Biological activity</term>
<term>Biological receptor</term>
<term>Cinnamomum</term>
<term>Extract</term>
<term>In vitro</term>
<term>Infection</term>
<term>Lentivirus</term>
<term>Medicinal plant</term>
<term>Plant origin</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Transferrin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Extrait</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Infection</term>
<term>Origine végétale</term>
<term>Plante médicinale</term>
<term>Transferrine</term>
<term>Récepteur biologique</term>
<term>Activité biologique</term>
<term>Antiviral</term>
<term>Cinnamomum</term>
<term>Lentivirus</term>
<term>In vitro</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC<sub>50S</sub>
, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC<sub>50S</sub>
, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC<sub>50S</sub>
, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MIN ZHUANG</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HONG JIANG</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SUZUKI (Yasuhiro)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>XIAOGUANG LI</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PENG XIAO</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TANAKA (Takashi)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HONG LING</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BAOFENG YANG</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SAITOH (Hiroki)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LIANFENG ZHANG</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>CHUAN QIN</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SUGAMURA (Kazuo)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>HATTORI (Toshio)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Microbiology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institute of Laboratory Animal Science, Chinese Academy of Medical Science</s1>
<s2>Beijing, 100021</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Graduate School of Biomedical Sciences, Nakasaki University</s1>
<s2>Nakasaki, 852-8131</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pharmacology, Harbin Medical University</s1>
<s2>Harbin, 150086</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Immunology, Tohoku University</s1>
<s2>980-8574</s2>
<s3>JPN</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>73-81</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000184929350100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0210832</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC<sub>50S</sub>
, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC<sub>50S</sub>
, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC<sub>50S</sub>
, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Extrait</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Extract</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Extracto</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Infection</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Infection</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Infección</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Origine végétale</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Plant origin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Origen vegetal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Plante médicinale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Medicinal plant</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Planta medicinal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Transferrine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Transferrin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Transferrina</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur biologique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Biological receptor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor biológico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Cinnamomum</s0>
<s2>NS</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Cinnamomum</s0>
<s2>NS</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Cinnamomum</s0>
<s2>NS</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Lauraceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Lauraceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Lauraceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Dicotyledones</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Dicotyledones</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Dicotyledones</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Angiospermae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Angiospermae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Angiospermae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Spermatophyta</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Spermatophyta</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Spermatophyta</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Pharmacognosie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Pharmacognosy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Farmacognosia</s0>
<s5>37</s5>
</fC07>
<fN21><s1>152</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 09-0210832 INIST</NO>
<ET>Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection</ET>
<AU>MIN ZHUANG; HONG JIANG; SUZUKI (Yasuhiro); XIAOGUANG LI; PENG XIAO; TANAKA (Takashi); HONG LING; BAOFENG YANG; SAITOH (Hiroki); LIANFENG ZHANG; CHUAN QIN; SUGAMURA (Kazuo); HATTORI (Toshio)</AU>
<AF>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University/980-8574/Japon (1 aut., 3 aut., 4 aut., 5 aut., 9 aut., 13 aut.); Department of Medical Microbiology, Harbin Medical University/Harbin, 150086/Chine (1 aut., 7 aut.); Institute of Laboratory Animal Science, Chinese Academy of Medical Science/Beijing, 100021/Chine (2 aut., 10 aut., 11 aut.); Graduate School of Biomedical Sciences, Nakasaki University/Nakasaki, 852-8131/Japon (6 aut.); Department of Pharmacology, Harbin Medical University/Harbin, 150086/Chine (8 aut.); Department of Immunology, Tohoku University/980-8574/Japon (12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 2009; Vol. 82; No. 1; Pp. 73-81; Bibl. 3/4 p.</SO>
<LA>Anglais</LA>
<EA>We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC<sub>50S</sub>
, 283.4 ± 16.3 and 149.5 ± 13.5 μg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC<sub>50S</sub>
, 43.1 ±2.8 and 7.8 ± 0.3 μg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC<sub>50S</sub>
, 29.9 ± 3.3 and 41.3 ± 3.4 μM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.</EA>
<CC>002B02S05</CC>
<FD>Extrait; Virus syndrome respiratoire aigu sévère; Infection; Origine végétale; Plante médicinale; Transferrine; Récepteur biologique; Activité biologique; Antiviral; Cinnamomum; Lentivirus; In vitro</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Lauraceae; Dicotyledones; Angiospermae; Spermatophyta; Retroviridae; Pharmacognosie</FG>
<ED>Extract; Severe acute respiratory syndrome virus; Infection; Plant origin; Medicinal plant; Transferrin; Biological receptor; Biological activity; Antiviral; Cinnamomum; Lentivirus; In vitro</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Lauraceae; Dicotyledones; Angiospermae; Spermatophyta; Retroviridae; Pharmacognosy</EG>
<SD>Extracto; Severe acute respiratory syndrome virus; Infección; Origen vegetal; Planta medicinal; Transferrina; Receptor biológico; Actividad biológica; Antiviral; Cinnamomum; Lentivirus; In vitro</SD>
<LO>INIST-18839.354000184929350100</LO>
<ID>09-0210832</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000221 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000221 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0210832
   |texte=   Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri